Intervention

Abatacept

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 60 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials60
Recruiting2
Common conditions22
Lead sponsors shown15
Advertisement

Clinical trials

60 shown
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyNCT07138898 · 2025-12-12
RECRUITING
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseNCT03414502 · 2007-12-10
RECRUITING
Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy SubjectsNCT06929039 · 2024-07-04
COMPLETED
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 DiabetesNCT03929601 · 2023-10-30
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid ArthritisNCT05451615 · 2022-09-30
UNKNOWN
COVID-19 VaccinE Response in Rheumatology PatientsNCT05080218 · 2021-11-15
COMPLETED
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to MethotrexateNCT04909801 · 2021-09-15
ACTIVE_NOT_RECRUITING
Early Markers of Disease and Response to TherapyNCT04118153 · 2021-03-05
COMPLETED
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs AbataceptNCT04529863 · 2020-08-17
COMPLETED
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs AbataceptNCT04529876 · 2020-08-17
COMPLETED
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs AbataceptNCT04529902 · 2020-08-17
COMPLETED
Effects of Abatacept on Myocarditis in Rheumatoid ArthritisNCT03619876 · 2019-07-10
TERMINATED
Rheumatoid Arthritis Memory B Cells and AbataceptNCT03652961 · 2019-06-02
COMPLETED
A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid ArthritisNCT03882008 · 2019-05-23
COMPLETED
A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different ProcessesNCT03714022 · 2018-11-09
COMPLETED
APRIL (AbatacePt in Rheumatoid Arthritis-ILD)NCT03084419 · 2018-06-26
UNKNOWN
Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)NCT03492658 · 2018-05-17
COMPLETED
Treatment Tapering in JIA With Inactive DiseaseNCT02840175 · 2017-05-18
COMPLETED
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDsNCT03086343 · 2017-05-09
COMPLETED
Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered SubcutaneouslyNCT02805010 · 2016-10-01
UNKNOWN
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life SettingNCT02037737 · 2016-09-30
COMPLETED
Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis PatientsNCT02547493 · 2016-03-03
COMPLETED
Inhibition of Co-Stimulation in Rheumatoid ArthritisNCT02652273 · 2016-01-01
UNKNOWN
Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid ArthritisNCT02557100 · 2015-11-19
COMPLETED
Effects of Abatacept in Patients With Early Rheumatoid ArthritisNCT02504268 · 2015-09-03
COMPLETED
Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South AfricaNCT02598466 · 2015-07-01
COMPLETED
Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or AbataceptNCT02353780 · 2015-03-01
TERMINATED
Treatment of Resistant Hypertension by Prevention of T-Cell Co-StimulationNCT02232880 · 2014-08-01
TERMINATED
Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir BackgroundNCT02053727 · 2014-07-01
WITHDRAWN
Post-marketing Study Assessing the Long-Term Safety of AbataceptNCT02169544 · 2014-01-31
COMPLETED
Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II StudyNCT02027298 · 2013-11-01
WITHDRAWN
Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled SyringeNCT01890473 · 2013-07-01
COMPLETED
Abatacept Post-marketing Clinical Study in JapanNCT01758198 · 2013-04-11
COMPLETED
Methotrexate-Inadequate Response Autoinjector Device Sub StudyNCT01844895 · 2013-04-01
COMPLETED
Real-world Clinical Efficacy of Abatacept in the T3 Data RegistryNCT01555879 · 2012-03-01
COMPLETED
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)NCT01350804 · 2011-09-01
COMPLETED
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.NCT01295151 · 2011-08-01
COMPLETED
Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid ArthritisNCT01142726 · 2010-12-01
COMPLETED
Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of AbataceptNCT01221636 · 2010-10-01
WITHDRAWN
Abatacept Versus Adalimumab Head-to-HeadNCT00929864 · 2009-10-01
COMPLETED
A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler UltrasonographyNCT00767325 · 2008-12-01
COMPLETED
Phase IIIB Switching From Intravenous to Subcutaneous StudyNCT00663702 · 2008-05-01
COMPLETED
Long Term Experience With Abatacept in Routine Clinical PracticeNCT02109666 · 2008-03-01
COMPLETED
Phase IIIB Subcutaneous Missed Dose StudyNCT00533897 · 2007-11-01
COMPLETED
A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to MethotrexateNCT00420199 · 2007-05-01
COMPLETED
Substudy - Low Dose of Abatacept in Subjects With Rheumatoid ArthritisNCT00989235 · 2007-04-01
COMPLETED
A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateNCT00409838 · 2007-04-01
COMPLETED
A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid ArthritisNCT00484289 · 2006-12-01
COMPLETED
A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving MethotrexateNCT00345748 · 2006-06-01
COMPLETED
Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)NCT00254293 · 2006-01-01
COMPLETED
Islet Transplantation Using AbataceptNCT00276250 · 2005-12-01
COMPLETED
Remission and Joint Damage Progression in Early Rheumatoid ArthritisNCT00122382 · 2005-07-01
COMPLETED
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF TherapyNCT00124982 · 2005-04-01
COMPLETED
Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult PatientsNCT00124449 · 2005-02-01
COMPLETED
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid ArthritisNCT00095173 · 2003-12-01
COMPLETED
An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF TherapyNCT00162201 · 2003-10-01
COMPLETED
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to MethotrexateNCT00048568 · 2002-12-01
COMPLETED
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.NCT00048581 · 2002-12-01
COMPLETED
The Study of Abatacept in Combination With EtanerceptNCT00162279 · 2000-10-01
COMPLETED
Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid ArthritisNCT00279760
COMPLETED

Common conditions

Rheumatoid Arthritis44Arthritis, Rheumatoid4Rheumatoid Arthritis (RA)3Type 1 Diabetes Mellitus2Abatacept1Active Rheumatoid Arthritis1Chronic Hepatitis B1Hypertension1Inflammatory Arthritis1Interstitial Lung Disease1Juvenile Idiopathic Arthritis1Juvenile Rheumatoid Arthritis1Myocardial Inflammation1Primary Sjogren's Syndrome1Psoriatic Arthritis1Rheumatic Disease1Rheumatic Diseases1Rheumatoid Arthritis (RA1Secondary Sjogren's Syndrome1Spondylarthritis1Treatment Compliance1Type 1 Diabetes1

Trial status mix

COMPLETED46
UNKNOWN4
TERMINATED3
WITHDRAWN3
ACTIVE_NOT_RECRUITING2
RECRUITING2

Phase mix

PHASE322
PHASE211
PHASE410
PHASE18
NA2
EARLY_PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.